Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICTCAR 014

Next Previous
X
Search
Drug Profile

ICTCAR 014

Alternative Names: Anti-CD19-anti-PD1 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics; Armored dnPD1+CD19CAR construct; dnPD1 armored anti-CD19 CAR-T Cell; Dominant Negative PD-1 Armored CAR-T; ICTCAR014

Latest Information Update: 28 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Cellular Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (Parenteral)
  • 04 Dec 2019 Innovative Cellular Therapeutics plans a phase I/II trial for Non-Hodgkin's Lymphoma (Second-line therapy or greater) in USA in first half of 2020
  • 04 Dec 2019 The US FDA approves IND application for ICTCAR 014 in Non-Hodgkin's lymphoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top